Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q3 FY24 results · Oct–Dec 2023
Natco Pharma reported revenue from operations of ₹758.60 crore (up 54.0% from Q3 FY23) and net profit of ₹212.70 crore (up 241.4% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 758.60 | 492.50 | +54.0% | 1,031.40 | −26.4% |
| Other income | 37.00 | 20.80 | +77.9% | 29.40 | +25.9% |
| Total income | 795.60 | 513.30 | +55.0% | 1,060.80 | −25.0% |
| Profit before tax | 256.30 | 81.40 | +214.9% | 439.60 | −41.7% |
| Net profit for the period | 212.70 | 62.30 | +241.4% | 369.00 | −42.4% |
| EPS, basic (₹) | 11.88 | 3.41 | +248.4% | 20.60 | −42.3% |
| Net margin (%) | 28.0 | 12.6 | 35.8 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 625.30 | 413.00 | +51.4% | 930.50 | −32.8% |
| Other income | 29.50 | 18.60 | +58.6% | 24.70 | +19.4% |
| Total income | 654.80 | 431.60 | +51.7% | 955.20 | −31.4% |
| Profit before tax | 223.60 | 45.00 | +396.9% | 424.00 | −47.3% |
| Net profit for the period | 192.00 | 37.30 | +414.7% | 360.20 | −46.7% |
| EPS, basic (₹) | 10.72 | 2.04 | +425.5% | 20.11 | −46.7% |
| Net margin (%) | 30.7 | 9.0 | 38.7 |
Consolidated
- Filed with BSE
- 15 Feb 2024, 10:51 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Feb 2024, 10:51 IST
- Board meeting
- 14 Feb 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE